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Abstract
Background: The nationwide German disease management program (DMP) for type 2 diabetes was introduced in
2003. Meanwhile, results from evaluation studies were published, but possible baseline differences between DMP
and usual-care patients have not been examined. The objective of our study was therefore to find out if patient
characteristics as socio-demographic variables, cardiovascular risk profile or motivation for life style changes
influence the chance of being enrolled in the German DMP for type 2 diabetes and may therefore account for
outcome differences between DMP and usual-care patients.
Methods: Case control study comparing DMP patients with usual-care patients at baseline and follow up; mean
follow-up period of 36 ± 14 months. We used chart review data from 51 GP surgeries. Participants were 586 DMP
and 250 usual-care patients with type 2 diabetes randomly selected by chart registry. Data were analysed by
multivariate logistic and linear regression analyses. Significance levels were p ≤ 0.05.
Results: There was a better chance for enrolment if patients a) had a lower risk status for diabetes complications,
i.e. non-smoking (odds ratio of 1.97, 95% confidence interval of 1.11 to 3.48) and lower systolic blood pressure
(1.79 for 120 mmHg vs. 160 mmHg, 1.15 to 2.81); b) had higher activity rates, i.e. were practicing blood glucose
self-monitoring (1.67, 1.03 to 2.76) and had been prescribed a diabetes patient education before enrolment (2.32,
1.29 to 4.19) c) were treated with oral medication (2.17, 1.35 to 3.49) and d) had a higher GP-rated motivation for
diabetes education (4.55 for high motivation vs. low motivation, 2.21 to 9.36).
Conclusions: At baseline, future DMP patients had a lower risk for diabetes complications, were treated more
intensively and were more active and motivated in managing their disease than usual-care patients. This finding
a) points to the problem that the German DMP may not reach the higher risk patients and b) selection bias may
impair the assessment of differences in outcome quality between enrolled and usual-care patients. Suggestions for
dealing with this bias in evaluation studies are being made.
Background
Sufficient evaluation is a precondition for deciding
whether the implementation of any new health care pol-
icy was successful. Policy makers depend on this scienti-
fic evidence, but their decisions sometimes restrain
researchers from generating evidence in a valid way. This
is the case with the nationwide disease management
program (DMP) for type 2 diabetes, which was intro-
duced in Germany in 2003.
The DMP was started in a rush with no preceding
randomized controlled trial to evaluate its effectiveness.
Instead, the program immediately became a regular part
of the statutory health care system, which covers 86% of
the German population [1]. This decision prohibited a
proper evaluation of its effects as we will describe later.
Nevertheless, researchers have designed several evalua-
tion projects and recent publications suggest that the
German DMP is a highly effective intervention: DMP
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any medium, provided the original work is properly cited.patients are supposed to have fewer and shorter hospital
stays as well as less microvascular and cardiovascular
complications [2]. Enrolment in the DMP is also sup-
posed to lead to a better health-related quality of life [3]
and may even result in a significant reduction in mortal-
ity compared to care as usual [4]. But these conclusions
may be premature, as the studies did not consider selec-
tion effects regarding the inclusion of patients in the
DMP.
A comprehensive description of the history and design
of the German DMP is found in another paper [5]. In
short, the DMP is a complex intervention including dif-
ferent medical services, e.g. regular foot and eye examina-
tions, rules for referrals to specialists and participation in
diabetes education courses. Enrolment in the DMP is
voluntary for physicians and patients, but endorsed with
financial incentives for both. According to latest data, in
August 2009 approximately 64% of the estimated five
million statutory insured patients with type 2 diabetes
were enrolled in the program [6].
The population-based approach of the German DMP
is somewhat restricted as the law states that only those
patients should be included who will participate actively
a n da r ee x p e c t e dt ob e n e f i tf r o mt h ep r o g r a m[ 7 ] .I ti s
up to the attending physicians to decide if and how they
apply these enrolment criteria. However, due to these
criteria it is conceivable that patients are not enrolled in
the DMP if their doctors consider them to be inactive
or rather non-compliant [8].
For health services research on DMP effectiveness this
implies that there may be baseline differences between
DMP and usual-care patients influencing the treatment
of their diabetes or their prognosis. Therefore non-
randomized observational studies may suffer from a
selection bias and differences in process and outcome
quality may result from different patient characteristics
in the two groups instead of program elements. For that
reason the question whether such a selection bias
regarding enrolment in the DMP exists is crucial for the
interpretation of study results [9].
The objective of our study was therefore to find out if
patient characteristics as socio-demographic variables,
cardiovascular risk profile or motivation for life style
changes influence the chance of being enrolled in the
German DMP for type 2 diabetes and to explore the
impact of this possible selection mechanism on DMP
effectiveness and the assessment of DMP outcome
measures.
Methods
The study is designed as a case-control study in which
DMP patients are compared with usual-care patients.
We collected present data and performed a retrospective
baseline assessment at the dates the DMP patients had
been enrolled. We chose the 30
th of June 2005 as the
index date for the selection of usual-care patients,
because it was estimated as mean date of enrolment of
the DMP patients. In the following we will refer to pre-
sent data as “t1“ and baseline data as “t0“. The study was
approved by the Ethics Committee of the Medical Asso-
ciation of Hamburg (reference number OB-008/07).
We randomly selected patients via chart registry from
51 primary care surgeries located in and around 4 larger
German cities (Hamburg, Bremen, Berlin and Düssel-
dorf). In each surgery we created a list of eligible patients
based on the electronic database of the GP. To be eligible
for the study the patients had to be treated for type 2 dia-
betes at least since June 2005 by their GP and they had to
have visited the GP surgery at least once in the last
12 months. Patients were excluded if they were no regu-
lar patients of the participating surgery, if they had severe
medical problems seriously affecting their ability to parti-
cipate in the study or if they were enrolled in the DMP
for shorter than 6 months at t1. From all eligible patients
we randomly selected a maximum of 25 DMP patients
and 25 usual-care patients and contacted them for writ-
ten informed consent to data collection based on the
documentation of their GP. However, since DMP partici-
pation rates were above 50% in most of the participating
surgeries, the number of eligible usual-care patients was
smaller than scheduled.
Altogether, 1141 DMP-patients and 917 usual-care
patients were contacted (cf. Figure 1). 60% of all con-
tacted patients (70% DMP and 46% usual-care patients)
agreed to participate in the study. Budget constraints
forced us to restrict the cluster size further to be able to
retain a high number of surgeries. For that reason we
randomly selected from all patients who agreed to parti-
cipate a maximum of 15 DMP and 15 usual-care patients
per surgery. In sum 217 DMP patients and 173 usual-
care patients were excluded for cluster size restrictions or
Agreed to participate 
803 (70%) 
Not accessible, 
no response or 
refused to participate  
338 (30%) 
Contacted 
1141 
Analysed 
586 
Excluded for cluster size (randomly)  
or exclusion criteria 
217 
DMP patients 
Not accessible, 
no response or 
refused to participate  
494 (54%) 
Usual-care patients 
Agreed to participate 
423 (46%) 
Analysed 
250 
Excluded for cluster size (randomly)  
or exclusion criteria 
173 
Contacted 
917 
Figure 1 Sampling and response rate.
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complied with exclusion criteria, i.e. DMP patients being
enrolled for less than 6 months or usual-care patients
with no diagnosis of diabetes at t0. In total, 586 DMP
patients and 250 usual-care patients were eligible for
inclusion. Recruitment and data collection took place
from 10
th of July 2007 to 16
th of June 2009.
Data collection
Data collection techniques included chart review and
interviews with GPs. For chart review the interviewers
used the GPs’ electronic and/or paper records and the
official DMP documentation sheets. For transferring the
collected data we used double data entry and additional
plausibility checks during and after data entry.
The data collected from chart review encompassed age,
gender, height, weight, duration of diabetes, co-morbidity
(e.g. depression and hypertension), smoking behaviour,
laboratory data of glycated haemoglobin (GHb) values,
blood pressure (BP) values, diabetic symptoms (polyuria,
polydipsia, fatigue), diabetes medication (insulin and/or
oral medication), glucose self-monitoring, and documen-
ted prescriptions for a diabetes patient education course.
For a proxy assessment of the patients’ general motiva-
tion regarding life style changes we asked the GPs to rate
the patients’ motivation for diabetes education on a
3 point scale (low, medium, high). Additionally, we asked
the GPs if their surgeries offered diabetes patient educa-
tion. We used this variable as a proxy measure for the
GPs’ knowledge and activity regarding diabetes.
Missing data
The data file included a certain amount of missing values.
Although 16 of 21 variables had less than 10% missing
values (cf. table 1), we identified a total of 357 complete
and 489 incomplete data sets. Complete and incomplete
data sets differed significantly regarding enrolment status
in the sense that DMP patients were more likely to have
complete data sets (cf. table 2). This phenomenon is a
result of the GPs’ inferior quality of patient documenta-
tion in usual-care patients outweighing our efforts to
include as much information as possible.
To reduce the possibility of misleading results based
on the distribution of missing data, we decided to
impute missing values by multiple imputation, which is
considered to be the statistically most valid imputation
method [10]. It has been argued that for research on
progressive diseases like type 2 diabetes, not more than
20% of missing values can be tolerated [11]. We there-
fore excluded all variables from the analyses that had a
total proportion of missing values of 21% and more.
In the imputation process, we created M = 100 data
sets with multivariate normal regression. We used a
total run length of 100,000 iterations with imputations
made after every 1,000
th iteration. We performed log
transformations to deal with non-normality of continu-
ous variables. Complete data were transformed back to
their original scales before analysis. We transformed
categorical variables to dummy variables and refitted
them to their scale after imputation [12].
The imputation model included all variables from the
complete data model including variables that could have
affected the response (e.g. depression) and additional
variables that were highly correlated (i.e. frequency of
GHb and BP measurements, diabetic symptoms, hyper-
tension as co-morbidity and body mass index). Age,
gender and enrolment status were used for the imputa-
tion model, but not imputed themselves.
Statistical analyses
We analysed differences in baseline characteristics
between DMP and usual-care patients by bivariate
Table 1 Missing cases in available data
t0 t1
Variable total
(n = 836)
usual-care
(n = 250)
DMP
(n = 586)
total
(n = 836)
usual-care
(n = 250)
DMP
(n = 586)
Duration of diabetes not applicable 5.2% 12.8% 2.1%
Co-morbidity: hypertension not determined 1.8% 1.2% 2.1%
Co-morbidity: depression not determined 1.8% 1.2% 2.1%
Smoking behaviour 10.3% 20.4% 6.1% 11.6% 18.4% 8.7%
GHb values 3.8% 10.4% 0.9% 2.7% 8.8% 0.2%
BP values 5.6% 16.8% 0.9% 3.9% 8.8% 1.9%
Diabetic symptoms 9.2% 18.4% 5.5% 7.9% 12.0% 6.3%
Oral medication 2.5% 5.6% 1.2% 0.9% 1.2% 0.9%
Insulin treatment 2.5% 5.6% 1.2% 1.1% 1.2% 1.0%
Glucose self-monitoring 7.6% 10.4% 6.5% 4.5% 4.4% 4.6%
Previous prescription of a patient education program 15.7% 22.4% 13.0% 9.8% 12.4% 8.9%
GP-rated motivation of the patients 20.7% 24.4% 19.3% 14.1% 13.6% 14.3%
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2-tests. The existence and the direction of a
selection bias were assessed using multivariate logistic
regression: DMP and usual-care patients were compared
at baseline regarding socio-demographic data (age and
gender), morbidity (depression and duration of diabetes),
risk status for diabetic complications (smoking beha-
viour, GHb and systolic BP values), treatment intensity
(medication), patient self-activity (earlier prescriptions of
a diabetes education program as well as urinary and
blood glucose self-monitoring) and the GP-rated moti-
vation of the patients to participate in a diabetes educa-
tion program. All factors were analysed in a unitary
statistical model and were therefore in each case
adjusted for the influence of the other variables. Addi-
tionally, the analysis was controlled for diabetes educa-
tion activity of the GP.
Concerning the impact of the selection bias, outcome
indicators were analysed by multivariate OLS regression
taking the observation periods between t0 and t1 into
account. To assess the outcome quality, we analysed the
course of GHb and systolic BP values in relation to
baseline values. Age, gender, duration of diabetes,
depression, medication (regarding GHb only), smoking
status (regarding BP only) and diabetes education activ-
ity of the GP were used as control variables.
To estimate the selection bias due to drop out we per-
formed ‘quasi’-intention to treat analyses for the assess-
ment of selection bias and outcome quality by treating
usual-care patients as DMP patients if they had ever
been enrolled in the DMP in the past. These analyses
used the same statistical modelling as described above.
All multivariate regression analyses accounted for stra-
tification of GP surgeries in four different cities and
reduced variance because of patient clustering in GP
surgeries. For all analyses an a-level of 5% (p ≤ 0.05)
was defined as statistically significant. Data analyses and
imputations of missing values were performed using
Stata 11.
We performed a power calculation for the outcome
analyses to ascertain that the final sample size (586
DMP patients and 250 usual-care patients) was suffi-
cient. Means and standard deviations of GHb (6.9 ±
1.2%) and systolic BP (140.6 ± 18.3 mmHg) were
derived from the German DETECT study [13]. To assess
the cluster effect we followed recommendations to
assume an intra class correlation of 0.04 in general prac-
tice [14]. We estimated a design effect of 1.64 using the
existing distribution of patients in surgeries. Following
results from the UKPDS study, we defined 1% in GHb
[15] and 10 mmHg in systolic BP [16] as clinically rele-
vant differences. Statistical power (1-b) for outcome dif-
ferences in both GHb and systolic BP was > 99%
considering the existing sample size.
Results
The analysis is based on 586 DMP patients and 250 usual-
care patients. The average observation period between t0
and t1 was 34 ± 17 months for DMP patients and 40 ± 5
months for usual-care patients, respectively. Due to the
study design (case-control study with retrospective base-
line) the calendar date of t0 varies for the study partici-
pants, i.e. the factual date of enrolment for DMP patients
and 30
th of June 2005 for usual-care patients. Usual-care
patients were significantly older at baseline (67.4 ± 12.5
years vs. 66.0 ± 10.3 years) and had a shorter duration of
illness than DMP patients (5.2 ± 5.5 years vs. 6.8 ± 7.2
years). 52.6% of the study participants were male. We
found no gender differences between DMP patients and
usual-care patients. Differences in baseline characteristics
between DMP and usual-care patients are shown in table 3.
Assessment of selection bias
I nt h el o g i s t i cr e g r e s s i o na n a l y s i sw ef o u n dt h a tm a n y
factors were associated with enrolment in the DMP for type
2 diabetes (cf. table 4). Patients with a lower risk for diabetic
complications had a better chance of being enrolled, i.e.
non-smokers (odds ratio 2.0) and patients with lower systo-
lic BP (1.8 for 120 mmHg vs. 160 mmHg). Furthermore,
treatment with oral medication (2.2) increased the likeliness
of enrolment. Other factors contributing to a higher
Table 2 Comparison of complete and incomplete data sets (t-test/c2-test)
Variable complete
(n = 357)
incomplete
(n = 489)
p
Age [in years]: mean ± standard deviation (SD) 69.3 ± 10.4 69.5 ± 11.5 n.s.
Women in % 47.3% 47.2% n.s.
DMP patients in % 78.7% 63.4% < 0.001
Duration of diabetes [in months]: mean ± SD 115 ± 86 110 ± 78 n.s.
GHb [in %]: mean ± SD 7.0 ± 1.1 6.9 ± 1.1 n.s.
Systolic BP [in mmHg]: mean ± SD 137 ± 17 139 ± 17 n.s.
Diastolic BP [in mmHg]: mean ± SD 79 ± 9 79 ± 10 n.s.
Motivation [3 = high through 1 = low]: mean ± SD 1.6 ± 0.8 1.6 ± 0.8 n.s.
n.s.: statistically not significant (p > 0.05)
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performing blood glucose self-monitoring (1.7) and having
been prescribed a diabetes education program (2.3). The
most important predictor for enrolment was the GP-rated
motivation of the patients to participate in a diabetes educa-
tion program (4.6 for high motivation vs. low motivation).
Despite the fact that bivariate analyses pointed at significant
differences in age, urinary glucose self-monitoring and dia-
betes duration (see above), these variables did not affect the
chance for enrolment in the multivariate analysis after
adjusting for possible confounders.
Outcome quality
We chose the course of GHb and systolic BP values
between t0 and t1 as indicators of outcome quality (cf.
table 5). We found a significant difference in the course
of systolic BP between DMP-patients and usual-care
patients. DMP patients had a statistically significant
lower systolic BP at baseline (139 mmHg vs. 144 mmHg
for usual-care patients) and DMP patients also showed a
greater decrease in systolic BP between t0 and t1,t h a t
was 3.6 mmHg higher than for usual-care patients. The
course of systolic BP was also influenced by the duration
of diabetes (i.e. +0.2 mmHg for every year of diabetes).
Table 3 Differences in baseline characteristics between DMP and usual-care patients
Variable usual-care patients
(n = 250)
DMP patients
(n = 586)
p*
Age (in years): mean ± standard deviation (SD) 67.4 ± 12.5
(n = 250)
66.0 ± 10.3
(n = 586)
0.041
Gender: men 128 (51.2%) 312 (53.2%) 0.588
Duration of diabetes (in years) ± SD 5.2 ± 5.5
(n = 218)
6.8 ± 7.2
(n = 574)
0.016
Co-morbidity: depression 28 (11.3%) 52 (9.1%) 0.313
Smoking behaviour: non-smoking 157 (78.9%) 466 (84.7%) 0.059
GHb value (in %) ± SD 6.9 ± 1.2
(n = 224)
7.0 ± 1.1
(n = 581)
0.153
Systolic BP value (in mmHg) ± SD 144 ± 23
(n = 208)
139 ± 17
(n = 581)
0.002
Oral medication 119 (50.4%) 384 (66.3%) < 0.001
Insulin dependency 32 (13.6%) 90 (15.5%) 0.471
Blood glucose self-monitoring 45 (20.1%) 158 (28.8%) 0.012
Urinary glucose self-monitoring 5 (2.2%) 55 (10.4%) < 0.001
Prescription of diabetes education before DMP start 25 (12.9%) 206 (40.4%) < 0.001
GP-rated motivation of the patients low: 148 (78.3%)
medium: 23 (12.2%)
high: 18 (9.5%)
low: 199 (42.1%)
medium: 156 (33.0%)
high: 118 (25.0%)
< 0.001
* Statistically significant results (p ≤ 0.05) in italic and bold letters.
Table 4 Factors associated with future enrolment in the DMP. Results from logistic regression analysis (n = 836)
Variable Odds ratio 95% confidence interval p*
Age: 60 vs. 70 years 1.12 0.91 to 1.37 0.254
Gender: men 1.09 0.71 to 1.68 0.681
Duration of diabetes: 10 years vs. 1 year 1.02 0.99 to 1.05 0.125
Co-morbidity: no depression 1.33 0.80 to 2.21 0.264
Smoking behaviour: non-smoking 1.97 1.11 to 3.48 0.021
GHb value: 7.0 vs. 8.0% 1.04 0.88 to 1.23 0.624
Systolic BP value: 120 vs. 160 mmHg 1.79 1.15 to 2.81 0.012
Oral medication** 2.17 1.35 to 3.49 0.002
Blood glucose self-monitoring 1.69 1.03 to 2.76 0.038
Urinary glucose self-monitoring 2.96 0.92 to 9.47 0.067
Prescription of diabetes education program before DMP start 2.32 1.29 to 4.19 0.006
GP-rated motivation of the patients: high vs. low (3 vs. 1 on a 3-point scale) 4.55 2.21 to 9.36 < 0.001
Diabetes education activity of the GP 1.23 0.71 to 2.14 0.456
* Statistically significant results (p ≤ 0.05) in italic and bold letters.
** Insulin treatment was dropped from the statistical model in favour of blood glucose self-monitoring because of high correlation between these two variables
(r
2 > 0.5) and blood glucose self-monitoring being the better predictor for enrolment.
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There was no change between t0 and t1 (i.e. 0.0 ±
1.1%). We found no statistical association between the
course of GHb and enrolment in the DMP. Indepen-
dent of the enrolment status the course of GHb values
over time was significantly associated with the patients’
medication (i.e. insulin treatment: +0.6%, oral medica-
tion +0.3%).
Comparison of available and imputed data sets
We compared the results of all analyses when based on
imputed data with those when based on available data.
There were considerable differences between the
results based on imputed compared to available data
(cf. table 6), however, the direction of the associations
stayed the same.
Quasi-intention-to-treat-analysis
We found 21 usual-care patients who temporarily had
been enrolled in the DMP before the study started. If
we count these patients as DMP patients, the results
from our analysis are only marginally different from the
results presented in this paper (cf. table 7).
Discussion
We found that before enrolment future DMP-patients
differed from usual-care patients in four dimensions.
Patients were more likely to be enrolled into the DMP
if they
1. had a lower risk status for diabetic complications
(i.e. non-smoking and lower systolic BP),
2. had higher self-activity rates (i.e. blood glucose
self-monitoring and having been prescribed a dia-
betes education program prior to the DMP),
3. were treated with oral medication and
4. had a higher GP-rated motivation regarding parti-
cipation in diabetes patient education.
All these dimensions are generally considered to have
a strong positive influence on treatment effects and on
the prognosis of diabetes.
We compared the chances for enrolment by odds
ratios, which are standard measures for these analyses.
Odds ratios are less intuitionally understood than risk
ratios because they are based on differences in odds, not
in likelihood as risk ratios (e.g. a number on a die has a
Table 5 Comparison of outcome quality in DMP and usual-care. Results from multivariate linear regression analyses
(n = 836)
Outcome indicators DMP versus usual-care patients (adjusted) 95% confidence interval p*
Course of GHb -0.11% -0.63 to 0.28 0.208
Course of systolic BP -3.57 mmHg -0.98 to -6.15 0.008
Adjusted for length of observation period between t0 and t1, age, gender, duration of diabetes, depression, medication (regarding GHb only), smoking status
(regarding BP only) and diabetes education activity of the GP.
* Statistically significant results (p ≤ 0.05) in italic and bold letters.
Table 6 Statistically significant differences between DMP and usual-care patients when using imputed and
available data
Imputed data Available data
Selection bias 1. Systolic BP value: 120 vs. 160 mmHg
(OR: 1.79 [95% CI: 1.15 to 2.81])
1. Systolic BP value: 120 vs. 160 mmHg
(OR: 1.99 [95% CI: 1.09 to 3.63])
2. Oral medication
(OR: 2.17 [95% CI: 1.35 to 3.49])
2. Oral medication
(OR: 2.32 [95% CI: 1.28 to 4.20])
3. Blood glucose self-monitoring
(OR: 1.69 [95% CI: 1.03 to 2.76])
3. Blood glucose self-monitoring
(OR: 3.40 [95% CI: 1.70 to 6.80])
4. Prescription of diabetes patient education
(OR: 2.32 [95% CI: 1.29 to 4.19])
4. Prescription of diabetes patient education
(OR: 2.64 [95% CI: 1.27 to 5.41])
5. GP-rated motivation of the patients: high vs. low
(3 vs. 1 on a 3-point scale)
(OR: 4.55 [95% CI: 2.21 to 9.36])
5. GP-rated motivation of the patients: high vs. low
(3 vs. 1 on a 3-point scale)
(OR: 6.96 [95% CI: 2.26 to 21.43])
6. Smoking behaviour: non-smoking
(OR: 1.97 [95% CI: 1.11 to 3.48])
6. No difference regarding smoking behaviour
7. No difference regarding urinary glucose self-monitoring 7. Urinary glucose self-monitoring
(OR: 5.68 [95% CI: 1.07 to 30.21])
Outcome quality 1. Course of systolic BP
(-3.57 mmHg [95% CI: -0.98 to -6.15])
1. No differences regarding course of systolic BP
OR: odds ratio; CI: confidence interval
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GP-rated high motivation vs. low motivation of the
patients means that a patient with high motivation has
4.55-times higher odds for enrolment than a person
with low motivation.
If exposure variables have a low prevalence (i.e. 5%
and below) odds ratios and risk ratios are comparable.
As the factors we identified in this study are common
(prevalence > 10%), the odds ratios (OR) presented in
table 4 do not approximate risk ratios (RR). It is possible
to convert OR into RR by accounting for the frequency
of each factor [17].
In doing this the 4.55 odds ratio (with a total preva-
lence of high motivation of 20.54% in the sample) trans-
lates to a 2.63 risk ratio. This means that a highly
motivated patient has 2.63-times higher likelihood for
enrolment than a person having a low motivation. As
we regard these differences still as highly clinically rele-
vant, we conclude that a selection bias has to be taken
into account when evaluating process and/or outcome
results of the DMP for type 2 diabetes in Germany.
However, the possibility of statistical adjustment for this
selection bias is limited, as we will discuss later on.
It is important to decide if the bias found in our study
mainly results from discontinuation of DMP enrolment
(drop out) [18] or from the GPs selection mechanisms
in clinical reality. Case-control studies (and all other
studies recruiting patients after the intervention started)
may suffer from a selection bias occurring when patients
systematically drop out of the intervention group before
data collection (e.g. because of low motivation or severe
illness). Therefore we examined this possibility in our
s t u d yb ya‘quasi’-intention to treat analysis counting
usual-care patients as DMP patients if they had ever
been enrolled in the DMP in the past. Both, assessment
of selection bias and analysis of outcome quality showed
similar results to our main analyses. We therefore sup-
pose that there is a considerable difference between
DMP and usual-care patients at baseline irrespective of
a selection bias due to drop out.
After assessing the selection bias, we investigated
selected outcome indicators to estimate the impact of
the selection bias. DMP patients had a lower systolic BP
at baseline (139 mmHg vs. 144 mmHg for usual-care
patients) and DMP patients also showed a greater
decrease in systolic BP between t0 and t1,t h a tw a s3 . 6
mmHg higher than for usual-care patients. The higher
BP reduction for DMP patients starting from a better
baseline value is difficult to interpret. On the one hand,
it could be interpreted as evidence for the effectiveness
of the DMP. On the other hand differences may be due
to selection effects. In the analysis of the course of BP
we controlled for the differences in BP at baseline in
order to reduce the selection bias, but this procedure
cannot be considered sufficient, because it is not possi-
ble to statistically control for the total selection effect.
The selection bias is multifaceted and statistical adjust-
ment cannot remove bias generated by factors that are
unmeasured or imprecisely measured. For example, we
do not know which measured or unmeasured factors
(e.g. differences in compliance, nutrition or physical
activity) may have led to the different BP values at base-
line and to what extent these factors resulted in a
greater decrease of systolic BP values in DMP patients
Table 7 Statistically significant differences between DMP and usual-care patients when using original and quasi-
intention-to-treat analyses sets
Original analyses Quasi-intention-to-treat analyses
Selection bias 1. Systolic BP value: 120 vs. 160 mmHg
(OR: 1.79 [95% CI: 1.15 to 2.81])
1. Systolic BP value: 120 vs. 160 mmHg
(OR: 1.95 [95% CI: 1.22 to 3.11])
2. Oral medication
(OR: 2.17 [95% CI: 1.35 to 3.49])
2. Oral medication
(OR: 2.60 [95% CI: 1.62 to 4.17])
3. Blood glucose self-monitoring
(OR: 1.69 [95% CI: 1.03 to 2.76])
3. Blood glucose self-monitoring
(OR: 1.83 [95% CI: 1.08 to 3.11])
4. Prescription of diabetes patient education
(OR: 2.32 [95% CI: 1.29 to 4.19])
4. Prescription of diabetes patient education
(OR: 2.88 [95% CI: 1.48 to 5.59])
5. GP-rated motivation of the patients: high vs. low (3 vs. 1
on a 3-point scale)
(OR: 4.55 [95% CI: 2.21 to 9.36])
5. GP-rated motivation of the patients: high vs. low (3 vs. 1
on a 3-point scale)
(OR: 4.64 [95% CI: 2.04 to 10.53])
6. Smoking behaviour: non-smoking
(OR: 1.97 [95% CI: 1.11 to 3.48])
6. No difference regarding smoking behaviour
7. No difference regarding urinary glucose self-monitoring 7. Urinary glucose self-monitoring
(OR: 3.78 [95% CI: 1.13 to 12.61])
Outcome quality 1. Course of systolic BP
(-3.57 mmHg [95% CI: -0.98 to -6.15])
1. Course of systolic BP
(-3.31 mmHg [95% CI: -1.01 to -5.63])
OR: odds ratio; CI: confidence interval
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therefore is that the existing selection bias of more
active and motivated DMP patients with a lower risk for
diabetic complications makes it impossible to decide if
the DMP is responsible for the differences in the course
of BP between DMP and usual-care patients.
Strengths and weaknesses of the study
Our study is the first study on the German DMP with a
baseline assessment before the individual start of the
DMP. This is important because a baseline assessment
is a precondition for estimating differences in patient
characteristics between the comparison groups which
could influence outcome quality. Another strength of
our study is the long observation period with a mean
time interval between t0 and t1 of 36 months.
We had an overall participation rate of 60% which is
above the published rate of 36% to 42% [19-21] in other
DMP studies. The participants in our study were not
selected by the GP or patients’ health care utilization
patterns since we used a chart registry approach rather
than a waiting room recruitment strategy. However,
DMP and usual-care patients had different response
rates, i.e. 70% of DMP and 46% of usual-care patients
agreed to participate in the study. In part, this difference
can be explained by the inferior patient documentation
in usual-care patients including more invalid postal
addresses for contact. The difference in response rates
may also be a part of the DMP selection bias: In both
groups the more active and motivated patients may also
be more often interested in study participation. For this
reason the number of usual-care patients with good self-
management may be larger in our study than it is de
facto. We thus may have even underestimated the selec-
tion bias.
Except for depression and hypertension, we did not
collect standardized data on the patients’ comorbidity.
We showed that patients with a higher risk for diabetic
complications are less likely to be in the DMP group.
Analogously the presence of burdensome comorbidity
might also keep patients from being enrolled into the
program and may therefore also contribute to the selec-
tion bias. This hypothesis should be analysed in further
research.
Interviewers were trained and monitored and we used
double data entry with additional plausibility checks. It
was not possible to get standardized clinical examina-
tions of the study participants because of the retrospec-
tive assessment. Instead, we used laboratory data for
GHb values and chart review data for the other vari-
ables. Other strengths of our study relate to a sufficient
statistical power, multivariate analyses dealing with pos-
sible confounding and an advanced treatment of missing
values.
We found considerable differences between imputed
and available data. Against the background of a biased
distribution of missing values (i.e. more missing values
in usual-care patients), we interpret the differences in
results when using available data as an effect of listwise
deletion of subjects with missing values in the regression
analyses. This bias was removed by multiple imputation.
For this reason, we consider the results from the ana-
lyses of the imputed data as more valid.
Comparison with other studies
Six studies on the effects of the German DMP on patients
with type 2 diabetes have been published up to now. Two
are observational studies based upon insurance claims
data. One (BEK claims [22]) is cross-sectional whereas
the other (ELSID claims [23]) is longitudinal but without
baseline assessment. The four other studies are based on
patient surveys, three of which are cross-sectional (BEK
survey [19], ELSID survey [20] and KORA survey [24])
and one is longitudinal but also without baseline assess-
ment (GMA survey [21]). Because of the missing baseline
assessment in all studies mentioned above, none of these
studies can distinguish between selection and program
effects.
However, the results of some of these studies pointed
at further dimensions of selection mechanisms in the
DMP. The authors of the BEK survey found a higher
level of education among DMP patients (e.g. 12% of
DMP patients and 8.2% of usual-care patients have an
university degree), explaining in part differences in
health status between DMP and usual-care patients.
Additionally there was a longer duration of diabetes
among DMP patients [19]. In our study, we also found a
longer duration of diabetes in DMP patients in a bivari-
ate analysis, but after adjusting for confounders in the
multivariate analysis, it did not contribute to the selec-
tion bias.
The BEK claims study focussed on comparisons of
morbidity between DMP and usual-care patients. DMP
patients were enrolled for 16 months on average. The
authors found more severe comorbidity (i.e. myocardial
infarction, heart failure, stroke as well as minor and
major amputations) in usual-care patients and a higher
rate of precursor diagnoses in DMP patients (i.e. angina
pectoris and chronic ischemic heart disease). They inter-
preted these findings as evidence for a better outcome
of DMP patients [22]. For methodical reasons, this inter-
pretation is not conclusive in a cross-sectional study.
In the study presented here we could show that future
DMP patients are more active and motivated already
before enrolment. We therefore presume that DMP
patients might have a better disease awareness and
more frequently search medical advice. Additionally, a
better medical surveillance is one of the main elements
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tion of precursor diagnoses, while highly severe diag-
noses as myocardial infarction or stroke are normally
identified independently of the patients’ awareness and
increased physicians’ surveillance in ambulatory care.
We therefore suggest that the results of the BEK claims
study should be interpreted in the sense of a selection
bias with a higher rate of highly severe diagnoses in
usual-care patients.
Conclusions
We conclude that self-active and motivated patients with
a lower risk for diabetic complications seem to be more
likely to be enrolled in the German DMP. The selection
mechanisms of the DMP in part reflect the legal regula-
tions. Policy makers explicitl yd e f i n e dt h a to n l ya c t i v e
patients with potential benefit should be enrolled. This
question touches aspects of appropriateness of care,
equity and accessibility to healthcare. The major clinical
implication of our results is that the disease management
program probably does not reach a considerable amount
of higher risk patients. In our view it is this patient sub-
group that has the biggest need of assistance and the lar-
gest room for improvement. For this reason it may be
important to develop the program further in the sense of
especially enrolling higher risk patients. We are aware
t h a tt h i sm a yb eas t r e n u o u se x e r c i s e .F u t u r er e s e a r c h
should focus on how to recruit this subgroup and how to
promote adherence to such a program.
The systematic selection and drop out mechanisms in
the DMP may lead to a bias in evaluation studies that
consists of two elements:
￿ in studies that recruit patients after the interven-
tion started, patients with inferior prognosis may
have systematically dropped out of the intervention
group before (retrospective) baseline assessment is
performed, and
￿ in non-randomized studies a largely increased rate
of patients with better prognosis may be in the inter-
vention group because of specific enrolment criteria
for the DMP.
Researchers who do not account for this bias may
wrongly interpret their results as program effects while
in fact they reflect the selection bias. The impact of the
selection bias can be reduced if randomization is not
possible. We suggest that future evaluation research
should at least
￿ have a baseline assessment before the intervention
takes place, so that the different starting points of
DMP and usual-care patients can be taken into
account, and
￿ ensure that all patients participating in the study
should meet the criteria for DMP enrolment as
applied in clinical reality, e.g. DMP and usual-care
patients in the study should have the same risk sta-
tus as well as comparable levels of motivation and
activity.
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